Publication | Closed Access

Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells

Tlr9 Agonist Dv281Cancer ImmunosurveillancePreclinical DevelopmentAllergyImmunologyImmunoeditingPulmonary PharmacologyBronchial NeoplasmImmunotherapeuticsImmunotherapyMedicineLung Cancer